Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch

• DOI: 10.1007/s13555-024-01330-w
• Publication Date: 2025-01-29T12:45:08Z
• Authors: Matthias Augustin; Maddalena Napolitano; Rosa Izu-Belloso; C. Elise Kleyn; Silvia Sabatino; Susanne Grond; Joaquin R. Otero-...; Chunyuan Liu; Ziad Reguiai; Toshifumi Nomura
• Keywords: Baseline (sea); Body surface area

Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score ≥ 7 ("BARI dominant") have been characterized as important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim evaluate quality life (QoL) functioning outcomes in adult patients BSA 40% NRS at baseline (BL) who received BARI 4 mg topical corticosteroid (TCS) combination trial BREEZE-AD7. BREEZE-AD7 was randomized, double-blind, placebo-controlled, parallel-group outpatient study involving AD once-daily placebo or 2-mg 4-mg TCS 16 weeks. eligible enrollment had 10%. This post-hoc analysis focused on 7. QoL impairment measured using Dermatology Life Quality Index (DLQI) 5, were assessed Work Productivity Activity Impairment (WPAI) questionnaire. Data reported descriptively. Last observation carried forward (LOCF) data reported, excluding collected after first rescue therapy date permanent drug discontinuation. Non-responder imputation used account missing data. At BL, high impairment. The mean DLQI BL indicates very large effect patients' QoL. experienced significant burden similar NRS. week 16, 61.5% treated indicated that it no only small their (DLQI 5), versus 24.1% receiving (p < 0.01). A decrease WPAI work − 41.6 7.0 observed also noticeable improvement daily activity 30.4 from compared placebo, achieved 12.2 Despite having baseline, itch-dominant showed marked benefits QoL, activity, function weeks treatment. Limitations include sample size analyzed.